Neurosense Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|
Revenue | $0 | $0 | $0 |
EBITDA | -3,030 | -2,994 | |
EBIT | -2,999 | ||
Net Income | -857 | -5,404 | -2,950 |
Net Change In Cash | 0 | 0 | 0 |
Cash | 1,208 | 771 | 2,640 |
Basic Shares | 18,055 | 15,405 | 15,379 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -97 | -89 | -3 | -3 |
EBITDA | -10,633 | -13,379 | -2,884 | -2,825 |
EBIT | -10,730 | -13,468 | -2,887 | -2,828 |
Net Income | -10,107 | -11,197 | -2,495 | -2,829 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -8,481 | -7,656 | -1,556 | -704 |
Cash | 2,640 | 3,543 | 11,063 | 699 |
Basic Shares | 13,640 | 11,504 | 1,940 | 1,940 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.11 |
2024-06-30 | -$0.02 |
2024-03-31 | -$0.35 |
2023-12-31 | -$0.16 |
